A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2018
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Biliary cancer; Liver cancer
- Focus Therapeutic Use
- 15 May 2018 Status changed from not yet recruiting to recruiting.
- 07 May 2018 Planned initiation date changed from 30 Apr 2018 to 31 Jul 2018.
- 03 Apr 2018 New trial record